Definitive Healthcare reported Q3 2026 revenue of $54.7 million, a 9% decrease year-over-year, while narrowing its net loss to $5.4 million. The company noted it will not provide forward guidance or host an earnings call due to a pending non-binding acquisition proposal from Advent International.
Term
Q3 2026
“Since joining Definitive, I’ve been focused on listening to our customers and our employees. What I’ve heard confirms my belief in the strength of our position in the market, and it has also shown me where we can execute better. This quarter’s results demonstrate the underlying health of the business and a solid foundation to build upon.”
For the nine months ended September 30, 2026, GRAIL reported total revenue of $123.0 million, a 19% increase year-over-year, primarily driven by screening revenue. The company recorded a net loss of $307.0 million, slightly improved from $309.2 million in the prior year, while maintaining a cash and marketable securities balance of approximately $788.7 million.
Maplebear Inc. (Instacart) reported a cash and cash equivalents balance of $830 million as of September 30, 2026, an increase from $637 million at the end of 2025. The filing highlights a proposed merger with DoorDash and notes that the company had 236,630,090 shares of common stock outstanding as of October 30, 2026.
Howard Hughes Holdings reported third quarter 2026 results, featuring the first full quarter of contributions from its Vantage insurance segment which added $315.8 million in net earned premiums. The company also announced a strategic shift for its real estate division, Howard Hughes Communities, toward an asset-light development and asset management platform through planned asset monetizations.
Paylocity reported first quarter fiscal 2027 total revenue of $451.7 million, representing 10.7% year-over-year growth. The company also highlighted the completion of its acquisition of Aidora Inc. and the repurchase of $152.5 million of its common stock during the quarter.
Term
Q1 2027
“Fiscal 27 is off to a strong start, with first quarter recurring & other revenue growth of 12.0% as we continue to see strong execution by our go-to-market teams, industry leading revenue retention, and product innovation that is bringing to market meaningful new AI-driven experiences and solutions that create differentiation and drive ARPU.”
Toby Williams, President and Chief Executive Officer
Airbnb, Inc. filed its Form 10-Q for the period ending September 30, 2026, identifying as a large accelerated filer. The report outlines a multi-year product roadmap and global expansion strategy, while highlighting risks related to macroeconomic conditions, foreign currency fluctuations, and the evolving regulatory environment for short-term rentals.
e.l.f. Beauty reported strong growth for the quarter ended September 30, 2026, with net sales increasing 51% year-over-year to $520.8 million. Net income rose significantly to $30.0 million compared to $3.0 million in the prior year period, driven by robust consumer demand and the integration of the rhode acquisition.
Pulse Biosciences reported a net loss of $66.3 million for the nine months ended September 30, 2026, compared to $55.3 million in the prior year period, driven by increased research and development expenses. The company significantly strengthened its balance sheet through an at-the-market offering program, raising $142.7 million and ending the period with $189.2 million in cash, cash equivalents, and marketable securities.
SoFi Technologies, Inc. reported 1,297,840,447 shares of common stock outstanding as of October 30, 2026. During the second quarter of 2026, the company expanded its platform through the acquisitions of Peach Finance, Inc. and Composer Securities LLC. The filing highlights a focus on navigating evolving regulatory environments, managing interest rate volatility, and continuing to grow its fee-based revenue and Loan Platform Business.
Sana Biotechnology reported third quarter 2026 financial results, highlighting a cash position of $121.7 million and a cash runway expected to last into mid-2027. The company is progressing toward initiating clinical trials for its type 1 diabetes candidate SC451 and its non-Hodgkin lymphoma candidate SG293, with data readouts anticipated in 2027.
“We continue to make meaningful progress toward initiating clinical studies of SC451 later this year and SG293 in 1Q 2027. We aim to share data from both of these programs in 2027 and anticipate both have the potential for relatively rapid proof of concept. In particular, SC451 in type 1 diabetes may provide a rapid signal, similar to what was seen with UP421, on whether the therapy can evade immune detection and function in patients.”
Steve Harr, Sana’s President and Chief Executive Officer
For the nine months ended September 30, 2026, Fidus Investment Corp reported total investment income of $136.9 million and net investment income of $64.5 million. Total net assets grew to $774.4 million, though net asset value per share slightly decreased to $19.47 from $19.55 at the end of 2025.
Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.
Term
Q3 2026
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
Full House Resorts reported third quarter 2026 consolidated revenues of $81.8 million, a 4.9% increase year-over-year, driven by record performance at American Place Casino. The company reported a net loss of $8.6 million, compared to a $7.7 million loss in the prior-year period, while Adjusted EBITDA remained relatively stable at $14.6 million.
Term
Q3 2026
“Our third quarter results reflect continued momentum across our portfolio, led once again by American Place. Since its opening in February 2023, revenues and profits at American Place have increased in every quarter when compared to the prior-year period.”
Daniel R. Lee, Chief Executive Officer of Full House Resorts
“At Chamonix/Bronco Billy’s, revenues grew across table games, food and beverage, hotel, retail, and several other departments. We are also executing on new initiatives to further advance our profit objectives at the property, while minimizing disruptions to customer service.”
Daniel R. Lee, Chief Executive Officer of Full House Resorts
Caribou Biosciences reported a net loss of $76.0 million for the nine months ended September 30, 2026, compared to $121.6 million in the prior year period. Total assets decreased to $123.0 million from $175.4 million at year-end 2025, while the company raised $22.8 million in net proceeds through an at-the-market (ATM) offering during the first nine months of 2026.
Pulse Biosciences reported third quarter 2026 financial results, highlighted by the completion of enrollment in its NANOPULSE-AF U.S. pivotal IDE study three months ahead of schedule. The company ended the quarter with $189.2 million in cash and equivalents, bolstered by $95.8 million in net proceeds raised through its ATM programs during the period.
“Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan. That speed reflects the growing enthusiasm physicians have shown for the nPulse catheter since their very first cases.”
Paul LaViolette, CEO and Co Chairman of Pulse Biosciences
“With NANOPULSE-AF fully enrolled, and the capital to execute, we are now focused on preparations for launch readiness, additional data readouts, and regulatory submissions.”
Paul LaViolette, CEO and Co Chairman of Pulse Biosciences
Caribou Biosciences reported Q3 2026 financial results, including a GAAP net loss of $26.6 million on revenue of $1.6 million. The company also highlighted its October 2026 decision to discontinue clinical trials for vispa-cel and CB-011 and reduce its workforce while exploring strategic alternatives such as a merger or acquisition.
EverCommerce reported Q3 2026 revenue of $151.4 million, a 2.7% increase year-over-year, though results fell below the low end of management's guidance due to milestone delays and softness in organic search customer acquisition. The company also announced it repurchased 1.6 million shares for $15.7 million during the quarter and recently increased its total buyback authorization by $25 million.
Term
Q3 2026
“Third quarter revenue was below the low end of our guidance, while Adjusted EBITDA came in at the midpoint. The revenue miss was driven primarily by non-MRR items, including vendor rebates and Security & Alarm milestone delays, along with continued softness in organic search–driven customer acquisition.”
Alex Goor, CEO of EverCommerce
“We’ve made meaningful changes to our leadership team over the last several months, and having spent time across our entire product portfolio, I’m excited by the potential in many areas of our business. We will invest dynamically as we identify opportunities to accelerate growth.”
Tenax Therapeutics reported a net loss of $50.2 million for the nine months ended September 30, 2026, driven by increased research and development costs for its cardiopulmonary therapies. Despite the loss, the company strengthened its liquidity position to $113.7 million in cash and cash equivalents, primarily through $52.1 million in proceeds from the exercise of warrants and options. Management believes current funds are sufficient to support operations for at least the next 12 months.
CytomX Therapeutics reported Q3 2026 financial results and provided a business update, highlighting that its lead candidate Varsetatug masetecan (Varseta-M) received FDA Fast Track designation for metastatic colorectal cancer. The company expects to provide a Phase 1 monotherapy data update in January 2027 and potentially initiate its first registrational study in the first half of 2027.
“Varseta-M is a first-in-class EpCAM-directed antibody drug conjugate with a topoisomerase-1 inhibitor payload, intentionally designed to improve the standard of care for patients with colorectal and other cancers. At CytomX, we are highly focused on rapidly advancing monotherapy Varseta-M towards a first registrational study in colorectal cancer.”
Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics
“Additionally, the Varseta-M development program continues to broaden, including an ongoing combination study with bevacizumab in mCRC and the initiation of Phase 1 expansion cohorts in gastric and gastroesophageal junction cancer, EpCAM-selected pancreatic ductal adenocarcinoma, and EpCAM-selected biliary tract cancer. Our integrated strategy is intended to urgently advance Varseta-M for the maximum benefit of cancer patients.”
Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics
Janux Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a strong cash position of $945.7 million. The company continues to advance its clinical pipeline, including dosing the first patient in a Phase 1 study of JANX013 and preparing for an upcoming data presentation for JANX011.
“During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007. We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans.”
David Campbell, Ph.D., President and Chief Executive Officer
Century Aluminum reported a significant increase in net income for the nine months ended September 30, 2026, reaching $873.1 million compared to $18.9 million in the prior year, largely driven by a $287.9 million gain on the sale of Hawesville and improved gross profits. Total net sales grew to $2,362.5 million from $1,894.2 million year-over-year, while the company's cash position strengthened to $713.0 million.
CareTrust REIT reported significant growth for the nine months ended September 30, 2026, with total revenues increasing to $480.5 million from $341.5 million in the prior year period. Net income attributable to the company rose to $252.9 million, supported by substantial real estate investment activity and common stock issuances that increased total assets to $7.7 billion.
Doximity reported revenue of $174.5 million for the quarter ended September 30, 2026, a slight increase from $168.5 million in the prior year. However, net income decreased significantly to $34.7 million compared to $62.1 million in the same period last year, driven by higher cost of revenue and increased research and development expenses.
Xeris Biopharma reported a significant increase in total revenue to $107.2 million for the third quarter of 2026, up from $74.4 million in the prior year. While the company achieved a net income of $11.3 million for the quarter, it recorded a net loss of $17.6 million for the nine-month period, largely driven by a $30.8 million loss on debt extinguishment.
Braemar Hotels & Resorts Inc. reported a significant net loss of $249.4 million for the quarter ended September 30, 2026, primarily driven by a $480 million termination fee. Total hotel revenue decreased to $101.6 million from $143.6 million in the prior year period, while the company recorded a $259.9 million gain on the disposition of assets and hotel properties.
Columbia Sportswear reported a significant increase in net income for the third quarter of 2026, reaching $84.7 million compared to $52.0 million in the prior year, driven by higher net sales and improved operating margins. The company also saw a substantial reduction in cash and short-term investments as it executed $200 million in share repurchases during the first nine months of the year.
Innodata reported record Q3 2026 revenue of $95.6 million, a 53% year-over-year increase, driven by significant expansion with hyperscale customers and new program wins. The company raised its full-year 2026 revenue growth guidance to 42% or more and highlighted new initiatives in physical AI and robotics data training.
Term
Q3 2026
“Q3 was another record revenue quarter for Innodata. Revenue of $95.6 million grew 53% year-over-year and exceeded analyst consensus by approximately $12.3 million, or 15%, marking our 13th consecutive quarter of year-over-year growth.”
Rahul Singhal, CEO
“The story of the quarter is the breadth of what we are winning. A customer that represented less than 5% of our revenue a year ago became our largest customer in Q3, giving us two customers of comparable scale and meaningfully advancing our diversification.”
Artivion reported Q3 2026 revenue of $123.8 million, a 9% increase year-over-year, driven by strong performance in On-X and stent grafts. The company narrowed its full-year 2026 revenue guidance to $484-$492 million and is preparing for the U.S. commercial launch of NEXUS in January 2027.
Term
Q3 2026
“In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.”
Pat Mackin, Chairman, President, and Chief Executive Officer
“Overall, we are encouraged by our third quarter performance and the progress we have made so far in 2026. With the recent PMAs of AMDS and NEXUS in the U.S., and ARCEVO LSA on track with enrollment in the ARTIZEN IDE trial, we believe we are on track to being the only company with a comprehensive aortic arch portfolio, which represents an approximately $330 million annual U.S. market opportunity.”
Pat Mackin, Chairman, President, and Chief Executive Officer
OppFi Inc. reported net revenue of $92.8 million for the three months ended September 30, 2026, a decrease from $104.6 million in the prior year period, primarily driven by a larger negative change in the fair value of finance receivables. The company maintained a strong liquidity position with $140.7 million in total cash and restricted cash, while total assets grew to $842.4 million following significant changes in its capital structure and the elimination of noncontrolling interests.
Visa Inc. identifies structural and organizational risks including the integration of acquisitions, the competitive market for AI and cybersecurity talent, and potential voting dilution from the conversion of class B and C common stock. The company also outlines its cybersecurity program, which is integrated into its enterprise risk management framework and aligned with ISO 27002 and PCI DSS standards.